PUBLIC COMPANY
save$ARVNARVINAS, INC.
$ARVN7.7350+3.13%New Haven, CT, USupdated 9h ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 11Phase 21pre_registration
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
- phase1A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- phase2A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
- phase2Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
🐶 Hiring Signal
next earnings Nov 4, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that